Clin Cancer Res. 2024 May 15;30(10):2288. doi: 10.1158/1078-0432.CCR-24-1089.
NO ABSTRACT
PMID:38745477 | DOI:10.1158/1078-0432.CCR-24-1089
Recent Content
- Genetic mutations do not hinder FLAG chemotherapy in rare blood cancer
- Cadonilimab combo boosts survival in advanced pancreatic cancer patients
- Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis
- New targeted therapy Ojemda approved in EU for pediatric glioma
- Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review
- Mo-Rez shows strong early responses in ovarian, endometrial cancers
- FDA grants fast track status to oral therapy for hard-to-treat myeloma
- Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
- Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis
- Advocacy group marks AML Awareness Day with interactive webpage launch